Sarter H, Kirschgesner J, Beaugerie L, Buisson A, Gower-Rousseau C, de Pouvourville Gérard
Public Health, Epidemiology and Economic Health Unit, CHU Lille, EPIMAD Registry, Maison Régionale de la Recherche Clinique, Lille, F-59000, France.
Department of Gastroenterology, Hôpital Saint-Antoine, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.
Qual Life Res. 2025 Feb;34(2):405-416. doi: 10.1007/s11136-024-03821-x. Epub 2024 Oct 29.
This study aimed to document utility values and the Visual Analog Scale (VAS) with the 5-level version of the EQ-5D questionnaire in a large sample of patients with inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC).
QALY-MICI was a cross-sectional survey across three sources in France. Data were collected between 2019 and 2022 for patients 18 and over. The EQ-5D-5 L, the EQ-VAS, the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), the Harvey-Bradshaw Index (HBI) for CD, and the Walmsley Index for UC (SCCAI) were collected.
A total of 2,841 patients aged over 18 were recruited (1785 with CD, 1056 with UC). The mean age was 40.2 (SD 14.3). The time since diagnosis was 6 years and over for 61.9% of patients. The most impacted dimensions were usual activities, anxiety/ depression, and pain/ discomfort. The mean utility value was 0.863 (SD 0.172) versus 0.905 (SD 0.158) in the French population (p = 0.007). The mean VAS value was 68 (SD 19.2) versus 73.4 (SD 22.2) in the general population (p = 0.016). Utility values and VAS were similar for CD and UC and higher for men. There was a strong positive correlation between utility values, the VAS, and the SIBDQ score, and a negative correlation between the HBI and the SCCAI. The SIBDQ score and disease activity were the main predictors of utility and VAS.
The QALY-MICI is, to our knowledge, the first study documenting utility values and VAS using the EQ-5D-5 L questionnaire on a large sample, with a comparison to the general population.
本研究旨在记录炎症性肠病(IBD)(包括克罗恩病(CD)和溃疡性结肠炎(UC))大样本患者使用EQ-5D问卷5级版本的效用值和视觉模拟量表(VAS)。
QALY-MICI是一项在法国三个来源进行的横断面调查。在2019年至2022年期间收集了18岁及以上患者的数据。收集了EQ-5D-5L、EQ-VAS、简短炎症性肠病问卷(SIBDQ)、CD的哈维-布拉德肖指数(HBI)以及UC的沃尔姆斯利指数(SCCAI)。
共招募了2841名18岁以上的患者(1785名CD患者,1056名UC患者)。平均年龄为40.2岁(标准差14.3)。61.9%的患者自确诊以来的时间为6年及以上。受影响最大的维度是日常活动、焦虑/抑郁和疼痛/不适。平均效用值为0.863(标准差0.172),而法国人群为0.905(标准差0.158)(p = 0.007)。平均VAS值为68(标准差19.2),而普通人群为73.4(标准差22.2)(p = 0.016)。CD和UC的效用值和VAS相似,男性更高。效用值、VAS与SIBDQ评分之间存在强正相关,HBI与SCCAI之间存在负相关。SIBDQ评分和疾病活动是效用和VAS的主要预测因素。
据我们所知,QALY-MICI是第一项使用EQ-5D-5L问卷在大样本中记录效用值和VAS并与普通人群进行比较的研究。